There’s a lot to know about OPZELURA! Which is why we have Dr. Cameron, dermatologist, break it down to help you get the best experience you can out of longer-term flare management with OPZELURA. Imagine that.
Dr. Cameron has been compensated for his time.
Managing Eczema Flares with OPZELURA
(ON-SCREEN TEXT)
OPZELURA (ruxolitinib) cream 1.5%
(ON-SCREEN TEXT)
OPZELURA may cause serious side effects, including:
Serious Infections: OPZELURA is in a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors can lower your ability to fight infections. Serious infections, some fatal, occurred when taking JAK inhibitors by mouth, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses. Some lung infections were seen in people using OPZELURA.
Before starting OPZELURA, tell your healthcare provider right away if you: have an infection (ie fever, sweating, chills), have diabetes, lung disease, HIV, or a weak immune system.
Increased risk of death in people age 50+ with at least one heart disease risk factor when taking JAK inhibitors by mouth.
Cancer and immune system problems: OPZELURA may increase your risk of certain cancers (lymphoma, lung, and skin) by changing the way your immune system works. Tell your doctor if you have had any type of cancer.
Increased risk of major cardiovascular events such as heart attack, stroke, or death in people age 50+ with at least one heart disease risk factor when taking JAK inhibitors by mouth, especially in current or past smokers.
Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen. This may be life-threatening. These types of blood clots occurred more often in people age 50+ with at least one heart disease risk factor when taking JAK inhibitors by mouth.
Important Safety Information will be discussed in more detail, later in this video.
(DESCRIPTION)
Dr. Cameron smiles at the camera as upbeat music softens as he speaks.
(SPEECH)
MICHAEL CAMERON: Hi, I'm Dr. Cameron, a dermatologist, and these are a few tips that can help you manage flares as you're using OPZELURA for mild to moderate eczema.
(ON-SCREEN TEXT)
Dr. Michael Cameron
Dermatologist
(DISCLAIMER)
This video is sponsored by Incyte Corporation. Dr. Cameron has been compensated for his time.
(SPEECH)
Eczema is a chronic condition, so treating it is all about keeping your flare-ups under control. Here's what you can do to help get the most out of your ongoing OPZELURA treatment for mild to moderate eczema.
(DISCLAIMER)
For the topical treatment of mild to moderate eczema in patients aged 12 and older without weakend immune systems.
(TITLE SLIDE)
Talk to a doctor
(SPEECH)
You should always talk to your own healthcare provider before starting this treatment. Let's talk about how to use OPZELURA.
(TITLE SLIDE)
All by itself
(SPEECH)
OPZELURA was studied for use on its own—not in combination with other eczema products.
(DISCLAIMER)
Use as directed by your healthcare provider.
(TITLE SLIDE)
Use it when you need it
(SPEECH)
When you're first using OPZELURA, apply it to the skin wherever you're experiencing eczema symptoms like on red, irritated skin or on itchy skin.
(DESCRIPTION)
A patient looks in her bathroom mirror, evaluating her facial eczema before applying OPZELURA.
(SPEECH)
OPZELURA should be applied as a thin layer to the skin.
(ON-SCREEN TEXT)
A thin layer
(DISCLAIMER)
For topical use only. Do not use in your eyes, mouth, or vagina. Apply twice daily as directed.
(DESCRIPTION)
The patient applies OPZELURA to her elbow, wrist, and calf. Dr. Cameron raises his hand with his fingers together, displaying a handprint.
(SPEECH)
You can apply that thin layer on up to 20% of your body's surface.
(ON-SCREEN TEXT)
Up to 20% BSA
(DISCLAIMER)
For topical use only. Do not use in your eyes, mouth, or vagina. Apply twice daily as directed. Do not use more than one 60 gram tube per week.
(SPEECH)
For reference, one of your handprints is about 1% of your body's surface area.
(ON-SCREEN TEXT)
20 of your handprints
(SPEECH)
Apply OPZELURA twice daily.
(ON-SCREEN TEXT)
Twice daily
(DISCLAIMER)
Use as directed by your healthcare provider.
(SPEECH)
Once your skin is clear, you should stop using OPZELURA.
(ON-SCREEN TEXT)
You should stop
(DISCLAIMER)
Majority of patients (54%) on OPZELURA achieved clear or almost clear skin at 8 weeks vs 15% not on product. Majority of patients (52%) felt meaningful itch relief at 8 weeks vs 15% not on product. Results may vary.
(DESCRIPTION)
The patient looks critically at her facial eczema in the bathroom mirror.
(SPEECH)
Talk with your healthcare provider if your eczema does not improve after eight weeks of using OPZELURA.
(DISCLAIMER)
Stop using OPZELURA when signs and symptoms of eczema, such as itching, rash, and redness go away, or as directed. Tell your healthcare provider if your symptoms do not improve within 8 weeks of treatment.
(SPEECH)
Just keep it handy for the next flare-up.
(DISCLAIMER)
Use as directed by your healthcare provider.
(TITLE SLIDE)
Be proactive
(SPEECH)
It might also help to use the printable treatment tracker from the staying on track page at OPZELURA.com.
(DESCRIPTION)
The patient smiles at her reflection, holding a tube of OPZELURA.
(SPEECH)
And take photos each week to share with your healthcare provider during your next visit.
(DESCRIPTION)
The patient itches her elbow, grimacing at the itch and irritation before we watch her apply OPZELURA.
(SPEECH)
As you continue applying OPZELURA during a flare-up, pay attention to how much is left in your tube.
(DISCLAIMER)
For topical use only. Do not use in your eyes, mouth, or vagina. Apply twice daily as directed. Do not use more than one 60 gram tube per week.
(SPEECH)
Be sure to fill your prescription so you can have a refill on hand when you need it.
(ON-SCREEN TEXT)
Refills
(DESCRIPTION)
Dr. Cameron smiles at the patient, who gives us a smile and a thumbs up.
(SPEECH)
Make sure you keep an eye on that.
(DISCLAIMER)
For topical use only. Do not use in your eyes, mouth, or vagina. Apply twice daily as directed. Do not use more than one 60 gram tube per week.
(TITLE SLIDE)
All set
(SPEECH)
OPZELURA is a single on-the-spot treatment that puts eczema relief at your fingertips. Imagine that.
(DISCLAIMER)
Results may vary.
(SPEECH)
Please continue watching for Important Safety Information.
(ON-SCREEN TEXT)
Please keep watching to view the full Important Safety Information next.
(SPEECH)
NARRATOR:
OPZELURA is a prescription medicine used on the skin (topical) for the short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis) in non-immunocompromised adults and children 12 years of age and older whose disease is not well controlled with topical prescription therapies or when those therapies are not recommended.
The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.
It is not known if OPZELURA is safe and effective in children less than 12 years of age with atopic dermatitis.
OPZELURA is for use on the skin only. Do not use OPZELURA in your eyes, mouth, or vagina.
OPZELURA may cause serious side effects, including:
Serious Infections: OPZELURA contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.
OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.
Increased risk of death due to any reason (all causes): Increased risk of death has happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking a medicine in the class of medicines called JAK inhibitors by mouth.
Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers have happened in people taking a medicine in the class of medicines called JAK inhibitors by mouth. People taking JAK inhibitors by mouth have a higher risk of certain cancers including lymphoma and lung cancer, especially if they are a current or past smoker. Some people have had skin cancers while using OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA. Limit the amount of time you spend in the sunlight. Wear protective clothing when you are in the sun and use a broad-spectrum sunscreen.
Increased risk of major cardiovascular events: Increased risk of major cardiovascular events such as heart attack, stroke, or death have happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and taking a medicine in the class of medicines called JAK inhibitors by mouth, especially in current or past smokers.
Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening. Blood clots in the vein of the legs (deep vein thrombosis, DVT) and lungs (pulmonary embolism, PE) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a medicine in the class of medicines called JAK inhibitors by mouth.
Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia). If needed, your healthcare provider will do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen.
Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides.
Before starting OPZELURA, tell your healthcare provider if you:
After starting OPZELURA:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of OPZELURA in people treated for atopic dermatitis include: common cold (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsillitis), and runny nose (rhinorrhea).
These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.
Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.
OPZELURA, the OPZELURA logo, Incyte, and the Incyte logo are registered trademarks of Incyte.
© 2024, Incyte. MAT-OPZ-02002 06/24
[END OF TRANSCRIPT]
OPZELURA is a prescription medicine used on the skin (topical) for the short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis) in non-immunocompromised adults and children 12 years of age and older whose disease is not well controlled with topical prescription therapies or when those therapies are not recommended.
The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.
It is not known if OPZELURA is safe and effective in children less than 12 years of age with atopic dermatitis.
OPZELURA is for use on the skin only. Do not use OPZELURA in your eyes, mouth, or vagina.
OPZELURA may cause serious side effects, including:
Serious Infections: OPZELURA contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.
OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.
Increased risk of death due to any reason (all causes): Increased risk of death has happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking a medicine in the class of medicines called JAK inhibitors by mouth.
Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers have happened in people taking a medicine in the class of medicines called JAK inhibitors by mouth. People taking JAK inhibitors by mouth have a higher risk of certain cancers including lymphoma and lung cancer, especially if they are a current or past smoker. Some people have had skin cancers while using OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA. Limit the amount of time you spend in the sunlight. Wear protective clothing when you are in the sun and use a broad-spectrum sunscreen.
Increased risk of major cardiovascular events: Increased risk of major cardiovascular events such as heart attack, stroke, or death have happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and taking a medicine in the class of medicines called JAK inhibitors by mouth, especially in current or past smokers.
Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening. Blood clots in the vein of the legs (deep vein thrombosis, DVT) and lungs (pulmonary embolism, PE) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a medicine in the class of medicines called JAK inhibitors by mouth.
Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia). If needed, your healthcare provider will do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen.
Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides.
Before starting OPZELURA, tell your healthcare provider if you:
After starting OPZELURA:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of OPZELURA in people treated for atopic dermatitis include: common cold (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsillitis), and runny nose (rhinorrhea).
These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.
Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.
